Stock:
Symbol Lookup
Register | Login
...
History
...
...

Pre Market | Dow Jones | Gold | Newsletters | Learn

Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.

OPKO Health - OPK - To acquire Cytochroma Inc.

Wednesday, January 9, 2013 11:47 AM
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. Replidea™ has been shown in a phase 2b clinical trial to effectively and safely treat SHPT and the underlying vitamin D insufficiency in pre-dialysis patients. Vitamin D insufficiency arises in CKD due to the abnormal upregulation of CYP24, an enzyme which destroys vitamin D and its metabolites. Studies in CKD patients have demonstrated that currently available over-the-counter and prescription vitamin D products cannot reliably raise blood vitamin D prohormone levels or effectively treat SHPT. "OPKO intends to market Replidea™ along with our proprietary point-of-care vitamin D diagnostic test currently in development," stated Phillip Frost, MD, CEO and Chairman. "We envision these remarkable products as part of the foundation for a new and markedly improved standard of care for chronic kidney disease patients having SHPT and/or hyperphosphatemia." Alpharen™ has been shown safe and effective in treating hyperphosphatemia in the phase 2 and 3 clinical trials undertaken to date in dialysis patients. Hyperphosphatemia (elevated serum phosphorus) exacerbates SHPT and promotes bone disease, soft tissue mineralization and progression of kidney disease. Approximately 90% of dialysis patients in the United States require regular treatment. Cytochroma's officers, including Charles W. Bishop, PhD, CEO, an authority on developing and commercializing successful new vitamin D therapies, and Eric J. Messner, MBA, having a noteworthy track record in pharmaceutical business development and in marketing and sales in the CKD arena, will join the OPKO management team. Prior to Cytochroma, Dr. Bishop and Mr. Messner held key positions at Bone Care International, Inc., a leader in vitamin D therapeutics acquired by Genzyme Corporation, now a division of Sanofi. About Cytochroma Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD.  About OPKO Health, Inc. - OPK OPKO (OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
PRINT

FREE Options Trading Lessons
I'll show you how to unlock HUGE Gains with Options Trading
Let's make 2015 the year you get RICH!

Latest Headlines

Eyes on China data, rate meetingsEyes on China data, rate meetings
LONDON (Reuters) - China`s battered stock markets reopen on Monday after a two-day public holiday and before a monthly data dump that could reinforce fears of a hard landing, rattling the global eco...
Lyft, Uber poach key Twitter engineers, managers amid turmoilLyft, Uber poach key Twitter engineers, managers amid turmoil
SAN FRANCISCO (Reuters) - Ride services Lyft and Uber have poached dozens of key Twitter Inc <TWTR.N> employees over the past year, including top engineering managers, to help personalize thei...
Janus's Gross says U.S. jobs data sufficient for 2015 Fed rate hike: CNBCJanus's Gross says U.S. jobs data sufficient for 2015 Fed rate hike: CNBC
NEW YORK (Reuters) - Bill Gross of Janus Capital Group Inc <JNS.N> said on Friday the August U.S. employment report was mediocre but decent enough to support the U.S. Federal Reserve`s case for ...
Betting on calm may worsen the stormBetting on calm may worsen the storm
NEW YORK (Reuters) - The dog days of summer turn out to have quite a bite, as investors have been roiled by the longest bout of volatility in U.S. equities in four years. The CBOE Volatility Index...
Nissan to recall about 300,000 vehicles in U.S. to fix console panelNissan to recall about 300,000 vehicles in U.S. to fix console panel
(Reuters) - Nissan Motor Co Ltd`s North America unit said it would recall about 300,000 vehicles in the United States and 28,000 vehicles in Canada to adjust a console panel. The affected vehicles h...

Loading Headlines...
 

Stock Market

Track the stock market today with the latest news and information on all things investing! Watch your stocks perform throughout the day and watch the breaking stock market news.

Feedback | disclaimer | privacy policy

Stock Market News

The Stock Market is ever changing. Keep up on your stock market news.

Stock Market Newsletters

Read up on your favorite stock market newsletters.


Learn the Stock Market

Sharper your stock trading skills with our stock market education section.